Recombinant activated factor VII as a hemostatic agent in very low birth weight preterms with gastrointestinal hemorrhage and disseminated intravascular coagulation

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 5, 2008, Pages 337-342

  Fischer, Doris ^a   Schloesser, Rolf ^a   Buxmann, Horst ^a   Veldman, Alex ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Disseminated intravascular coagulation; Gastrointestinal bleeding; Preterms; Recombinant activated factor VII

Indexed keywords

FRESH FROZEN PLASMA; HEMOSTATIC AGENT; OXIDIZED REGENERATED CELLULOSE; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ABSENCE OF SIDE EFFECTS; ACIDOSIS; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG TREATMENT FAILURE; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; GESTATIONAL AGE; HEMORRHAGIC SHOCK; HEMOSTASIS; HUMAN; HYPOTHERMIA; INFANT; INTESTINE NECROSIS; MALE; NECROTIZING ENTEROCOLITIS; NEONATAL INTESTINAL DISEASE; NEWBORN DISEASE; PREMATURITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT OUTCOME; VERY LOW BIRTH WEIGHT;

BIRTH WEIGHT; DISSEMINATED INTRAVASCULAR COAGULATION; FACTOR VIIA; GASTROINTESTINAL HEMORRHAGE; HEMOSTATICS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, VERY LOW BIRTH WEIGHT; RECOMBINANT PROTEINS; SHOCK, HEMORRHAGIC; TREATMENT OUTCOME;

EID: 43149096247     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181639b28     Document Type: Article

References (35)

1. Veldman A, Hoffman M, Ehrenforth S. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. Curr Med Chem. 2003;10:797-811.
2. Hoots WK. Challenges in the therapeutic use of a "so-called" universal hemostatic agent: recombinant factor VIIa. Hematology (Am Soc Hematol Educ Program). 2006;426-431.
3. Uhlmann EJ, Eby CS. Recombinant activated factor VII for non-hemophiliac bleeding patients. Curr Opin Hematol. 2004;11:198-204.
4. Kulkarni R, Aledort LM, Berntorp E, et al. Therapeutic choices for patients with hemophilia and high-titer inhibitors. Am J Hematol. 2001;67:240-246.
5. Chuansumrit A, Nuntnarumit P, Okascharoen C, et al. The use of recombinant activated factor VII to control bleeding in a preterm infant undergoing exploratory laparotomy. Pediatrics. 2002;110:169-171.
6. Olomu N, Kulkarni R, Manco-Johnson M. Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants. J Perinatol. 2002;22:672-674.
7. Veldman A, Fischer D, Voigt B, et al. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med. 2002;28:1635-1637.
8. Mitsiakos G, Papaioannou G, Giougi E, et al. Is the user of rFVIIa safe and effective in bleeding neonates. J Pediatr Haematol Oncol. 2007;29:145-150.
9. Filan PM, Mills JF, Clarnette TD, et al. Spontaneous liver hemorrhage during laparotomy for necrotizing enterocolitis: a potential role for recombinant factor VIIa. J Pediatr. 2005;147:857-859.
10. Roberts HR, Monroe DM, III, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol. 2004;41:101-108.
11. McLintock C. Postpartum haemorrhage. Thromb Res. 2005;115(suppl 1):65-68.
12. Tancabelic J, Haun SE. Management of coagulopathy with recombinant factor VIIa in a neonate with echovirus type 7. Pediatr Blood Cancer. 2004;43:170-176.
13. Bell MJ, Ternberg JC, Feisin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978;187:1-7.
14. Gordon PV, Swanson JR, Attridge JT, et al. Emerging trends in acquired neonatal intestinal disease: is it time to abandon Bell's criteria? J Perinatol. 2007;27:661-671.
15. Bakhtiari K, Meijers JC, de JE, et al. Prospective validation of the International Society of thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med. 2004;32:2416-2421.
16. Janota J, Stranak Z, Statecna B, et al. Characterization of multiple organ dysfunction syndrome in very low birthweight infants: a new sequential scoring system. Shock. 2001;15:348-352.
17. Levi M, de JE, van der PT. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med. 2004;36:41-49.
18. Ewer AK, Al-Salti W, Coney AM, et al. The role of platelet activating factor in a neonatal piglet model of necrotising enterocolitis. Gut. 2004;53:207-213.
19. Golino P, Ambrosio G, Ragni M, et al. Short-term and long-term role of platelet activating factor as a mediator of in vivo platelet aggregation. Circulation. 1993;88:1205-1214.
20. Ghosh S, Pendurthi UR, Steinoe A, et al. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J Biol Chem. 2007;282:11849-11857.
21. Chistolini A, Mazzucconi MG, Tirindelli MC, et al. Disseminated intravascular coagulation and myocardial infarction in a haemophilia B patient during therapy with prothrombin complex concentrates. Acta Haematol. 1990;83:163-165.
22. Hellstern P. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res. 1999;95:S7-S12.
23. Chuansumrit A, Visanuyothin N, Puapunwattana S, et al. Outcome of intracranial hemorrhage in infants with congenital factor VII deficiency. J Med Assoc Thai. 2002;85(suppl 4):S1059-S1064.
24. Wong WY, Huang WC, Miller R, et al. Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency. Haemophilia. 2000;6:50-54.
25. Hunseler C, Kribs A, Eifinger F, et al. Recombinant activated factor seven in acute life-threatening bleeding in neonates: report on three cases and review of literature. J Perinatol. 2006;26:706-713.
26. Razon Y, Erez E, Vidne B, et al. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Paediatr Anaesth. 2005;15:235-240.
27. Velik-Salchner C, Sergi C, Fries D, et al. Use of recombinant factor VIIa (Novoseven) in combination with other coagulation products led to a thrombotic occlusion of the truncus brachiocephalicus in a neonate supported by extracorporal membrane oxygenation. Anesth Analg. 2005;101:924.
28. Wittenstein B, Ng C, Ravn H, et al. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med. 2005;6:473-476.
29. Girisch M, Rauch R, Carbon R, et al. Refractory bleeding following major surgery of a giant sacrococcygeal teratoma in a premature infant: successful use of recombinant factor VIIa. Eur J Pediatr. 2004;163:118-119.
30. Millar CG, Stringer MD, Sugarman I, et al. The use of recombinant factor VIIa for bleeding in paediatric practice. Haemophilia. 2005;11:171-174.
31. Veldman A, Josef J, Fischer D, et al. A prospective pilot study of prophylactic treatment of preterm neonates with recombinant activated factor VII during the first 72 hours of life. Pediatr Crit Care Med. 2006;7:34-39.
32. Erhardtsen E. Ongoing NovoSeven trials. Intensive Care Med. 2002;28(suppl 2):S248-S255.
33. Villar A, Aronis S, Morfini M, et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia. 2004;10:352-359.
34. Godier A, Mazoyer E, Cymbalista F, et al. Recombinant activated factor VII efficacy and safety in a model of bleeding and thrombosis in hypothermic rabbits: a blind study. J Thromb Haemost. 2007;5:244-249.
35. Schreiber MA, Holcomb JB, Hedner U, et al. The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. J Trauma. 2002;53:252-257.